1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
OBJECTIVE
To prospectively assess the reproductive outcome with a small bolus of hCG administered on the day of oocyte retrieval after ovulation induction with a GnRH agonist (GnRHa).


METHODS
Prospective, randomized trial.


METHODS
Three hospital-based IVF clinics.


METHODS
Three hundred five IVF/intracytoplasmic sperm injection patients after a GnRH antagonist protocol.


METHODS
Ovulation induction was performed with either 10,000 IU hCG or 0.5 mg GnRHa (buserelin) supplemented with 1,500 IU hCG on the day of oocyte retrieval.


METHODS
Reproductive outcome in the two groups.


RESULTS
No significant differences were seen regarding positive hCG/ET rate (48% and 48%), ongoing pregnancy rate (26% and 33%), delivery rate (24% and 31%), and rate of early pregnancy loss (21% and 17%) between the GnRHa and 10,000 IU hCG groups, respectively.


CONCLUSIONS
A small bolus of hCG in the GnRHa group secured the luteal phase, resulting in a comparable reproductive outcome in the two groups. However, a nonsignificant difference of 7% in delivery rates justifies further studies to refine the use of GnRHa for ovulation induction.
Humaidan
Peter
P
The Fertility Clinic, Skive Regional Hospital, Resenvej 25, 7800 Skive, Denmark. peter.humaidan@sygehusviborg.dk
Ejdrup Bredkjaer
Helle
H
Westergaard
Lars Grabow
LG
Yding Andersen
Claus
C
D000328:Adult; D001755:Blastocyst; D006063:Chorionic Gonadotropin / Q000008:administration & dosage*; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D008183:Luteal Phase; D007986:Luteinizing Hormone / Q000097:blood; D054315:Oocyte Retrieval; D009865:Oocytes / Q000166:cytology; D016471:Ovarian Hyperstimulation Syndrome / Q000209:etiology; D010062:Ovulation Induction / Q000009:adverse effects / Q000379:methods*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011374:Progesterone / Q000097:blood; D011446:Prospective Studies; D012102:Reproductive Control Agents / Q000008:administration & dosage*; D020554:Sperm Injections, Intracytoplasmic
D006063:Chorionic Gonadotropin; D012102:Reproductive Control Agents; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone